Counseling Patients About Germline BRCA Mutations

Slides:



Advertisements
Similar presentations
What Do We Do? Cancer Genetics Service for Wales.
Advertisements

Clinical background: Patient RM, YoB 1966 Her family were originally referred because of a history of breast and ovarian cancer. BRCA testing found a missense.
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
BRCA2 Blue: Rad51; Green: BRCA2
BRCA Mutations and Breast Cancer Ruth Phillips and Patty Ashby.
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Volume 32, Number 19, July. 1, 2014, from J Clin Oncol Chen.
Pancreatic Cancer In 2012 there were 43,920 cases of pancreatic cancer. 10% of these cases have a family clustering of pancreatic cancers and associated.
Dr Tracie Miles % of women with OC will have a BRCA gene mutation (Zhang et al 2011) Women with this gene mutation often have more aggressive, fast-growing.
Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.
Hereditary Cancer Predisposition: Updates in Genetic Testing
Navigating from Somatic Tumor Testing to Germline Genetic Testing
Kyle Salsbery Genetic Counselor
Susan Domchek, MD University of Pennsylvania
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Introduction to Direct-to-Consumer Genetic Testing
State of the Art in BRCA-Mutated Ovarian Cancer
Timely Diagnosis of Gastroenteritis: Implications for Patients and Public Health.
Diabetic Dyslipidemia in Practice
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer
Advanced NSCLC Without Actionable Mutations
BRCA, HRR Deficiency, and PARP Inhibitors
Heart Rate, HF Admissions, and Readmissions
Does One Size Fit All in Obesity Management?
The Nurse View.
MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer
The Genomics of Cancer and Molecular Testing:
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
Genetics and Breast Cancer Adelphi 2018 Educational Forum Sharona Cohen, MS, CGC Certified Genetic Counselor Northwell Health.
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
What Do We Know About LDL-C?
PARP Inhibitors and Cancer: What Do You Need to Know?
Tailoring Hemophilia Prophylaxis Therapy
Optimizing Management of Advanced Bladder Cancer
Managing gBRCA-Positive Metastatic Breast Cancer
Individualizing Care in Ovarian Cancer
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Mutational Testing to Select Novel Targeted Therapies in AML
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Innovations in Home Care
Clinicians' Corner in Dyslipidemia
Maintenance Therapy in Advanced Ovarian Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
PARP Inhibitors.
The Role of IDH Inhibitors in Hematologic Malignancies
Cancer-Associated Thrombosis
CAD and HF Often Coexist
Molecular Testing in Ovarian Cancer: Is the Time Now?
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
New ELN Recommendations
The Changing Field of Melanoma: Ipilimumab.
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
Add-On Therapy to Insulin in T1DM Management
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Specific Tumor Suppressor Genes
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
HBOC Genetic counseling: major concerns and communication skills
Identifying TRK Fusions in Head and Neck Cancer
Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Breast Cancer BRCA testing protocol
Breast cancer BRCA testing protocol
A, Proportion of variants detected in the MMR genes.
Shared-Decision Making in Dyslipidemia
Prevalence of gBRCA1/2 mutations stratified by (A) FIGO stage, and (B) family history of cancer. Prevalence of gBRCA1/2 mutations stratified by (A) FIGO.
Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.
Presentation transcript:

Counseling Patients About Germline BRCA Mutations

Risk of Malignancy in Persons With a Germline BRCA1 or BRCA2 Pathogenic Variant

Rationale for Genetic Testing for BRCA Mutation

Approaches to Molecular Testing

Genetic Testing Guidelines for Ovarian Cancer

BRCA1/2 Testing Criteria

BRCA1/2 Testing Criteria (cont)

Patient Education About Genetic Testing

Possible Test Results

Patient Education After Genetic Testing

Implications for Family Members

Management Considerations

Management Considerations (cont)

Management Considerations: PARP Inhibitor Therapy for Ovarian Cancer

Follow-Up Discussions

Summary

Resources for Clinicians and Patients

Abbreviations